Ace Therapeutics Expands Preclinical Ophthalmology Services With AAV Gene Therapy Capabilities
Key Points
- Ace Therapeutics added integrated AAV vector development and ocular gene therapy services to its preclinical ophthalmology offering.
- The platform covers vector engineering, production, purification, formulation and safety evaluation, with AI used to optimize delivery and transduction.
- Expanded ophthalmic assessment tools including OCT, fluorescein angiography and visual function testing support integrated preclinical programs.
Ace Therapeutics has expanded its preclinical ophthalmology research capabilities with the addition of integrated adeno-associated virus (AAV) vector development and ocular gene therapy services. The contract research organization (CRO) aims to provide pharmaceutical and biotechnology researchers with coordinated support for evaluating ocular drug candidates, from vector engineering and production through preclinical efficacy and safety assessments.
The expanded offering addresses several technical challenges associated with ocular gene therapy, including limited penetration into retinal tissues and inefficient gene delivery. Ace Therapeutics’ AAV development platform is designed to support the engineering and optimization of viral vectors for specific ocular applications, with an emphasis on improving transduction efficiency and targeted delivery.
The company’s services cover multiple stages of vector development, including vector selection and characterization, AAV production and purification, formulation development and drug delivery system screening. Its ocular-focused capabilities also include vector design, production, purification, titer determination and safety and toxicity evaluations.
Artificial intelligence (AI) technologies are incorporated into the discovery process to help accelerate vector development and support optimization across several parameters, including delivery performance, transduction efficiency and immunogenicity.
Ace Therapeutics offers recombinant AAV (rAAV) vector development programs that can be tailored to individual gene therapy applications. The platform is intended to support research across a range of ophthalmic conditions, including inherited retinal diseases, age-related macular degeneration (AMD), diabetic retinopathy and glaucoma.
By providing customized vector engineering and production services, the CRO aims to help researchers address disease-specific delivery requirements and advance gene therapy candidates through preclinical evaluation.
Alongside its vector development capabilities, Ace Therapeutics has expanded the role of its ophthalmic technology platform, which provides a range of tools for assessing ocular structure and function in preclinical models. Available evaluation methods include slit-lamp biomicroscopy, optical coherence tomography (OCT), tonometry, fluorescein angiography and fundus photography. The platform also incorporates optokinetic and optomotor response testing, along with other visual behavioral assessments. These techniques allow researchers to examine changes in ocular anatomy, retinal structure and visual function during preclinical studies. Many of the available procedures are non-invasive or minimally invasive, supporting repeated assessments and data collection throughout a study. Testing protocols can be configured around individual research objectives, allowing investigators to select the imaging and functional measurements most relevant to a particular drug candidate or disease model.
The combination of AAV vector engineering and ocular assessment capabilities gives Ace Therapeutics an integrated service offering for preclinical ophthalmology programs. Researchers can access individual technical services or combine multiple capabilities under a coordinated development program. By bringing vector design and production together with imaging, functional testing and safety evaluations, the company aims to help clients generate the data needed to assess therapeutic performance and guide decisions during early-stage ocular drug development.
Learn more at www.acetherapeutics.com.
Total Page Views: 8

















